For a clinical-stage biopharmaceutical company that was depending on a binary outcome, 700m valuation was insane and look at us with a revenue generating asset and few more of them on the way we are lingering at 1.5b
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)